BLASZYK MICHAEL D 4

What Happened

• Michael D. Blaszyk, a director of ImmunityBio, was granted 65,600 shares as a derivative award on June 9, 2026. The reported acquisition price is $0.00 (award/derivative), so no cash was paid at grant. This is an equity compensation award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (appears timely).
• Security: 65,600 shares (derivative award), transaction type code A (award/grant).
• Price: $0.00 per share at grant (no immediate cash value recorded on the Form 4).
• Vesting: Per footnote — 100% of the shares will vest on the earlier of June 9, 2027 or the day before the next annual meeting, provided Blaszyk remains a “Service Provider” under the Issuer’s 2025 Equity Incentive Plan.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing exhibits/notes: Exhibit 24 (Power of Attorney) included.

Context

• This is a standard director equity grant for compensation and is a derivative award subject to service-based vesting; it does not represent a market purchase or sale. Such awards can align director incentives with shareholder interests but do not necessarily signal immediate insider sentiment about the stock. The award may have future economic value if the stock price rises and the vesting conditions are met.